RESUMO
Ensuring the homeostatic integrity of pulmonary artery endothelial cells (PAECs) is essential for combatting pulmonary arterial hypertension (PAH), as it equips the cells to withstand microenvironmental challenges. Spermidine (SPD), a potent facilitator of autophagy, has been identified as a significant contributor to PAECs function and survival. Despite SPD's observed benefits, a comprehensive understanding of its protective mechanisms has remained elusive. Through an integrated approach combining metabolomics and molecular biology, this study uncovers the molecular pathways employed by SPD in mitigating PAH induced by monocrotaline (MCT) in a Sprague-Dawley rat model. The study demonstrates that SPD administration (5 mg/kg/day) significantly corrects right ventricular impairment and pathological changes in pulmonary tissues following MCT exposure (60 mg/kg). Metabolomic profiling identified a purine metabolism disorder in MCT-treated rats, which SPD effectively normalized, conferring a protective effect against PAH progression. Subsequent in vitro analysis showed that SPD (0.8 mM) reduces oxidative stress and apoptosis in PAECs challenged with Dehydromonocrotaline (MCTP, 50 µM), likely by downregulating purine nucleoside phosphorylase (PNP) and modulating polyamine biosynthesis through alterations in S-adenosylmethionine decarboxylase (AMD1) expression and the subsequent production of decarboxylated S-adenosylmethionine (dcSAM). These findings advocate SPD's dual inhibitory effect on PNP and AMD1 as a novel strategy to conserve cellular ATP and alleviate oxidative injuries, thus providing a foundation for SPD's potential therapeutic application in PAH treatment.
Assuntos
Células Endoteliais , Monocrotalina , Poliaminas , Hipertensão Arterial Pulmonar , Artéria Pulmonar , Purinas , Ratos Sprague-Dawley , Espermidina , Remodelação Vascular , Animais , Espermidina/farmacologia , Espermidina/uso terapêutico , Purinas/farmacologia , Poliaminas/metabolismo , Masculino , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/metabolismo , Remodelação Vascular/efeitos dos fármacos , Artéria Pulmonar/efeitos dos fármacos , Artéria Pulmonar/metabolismo , Artéria Pulmonar/patologia , Ratos , Hipertensão Arterial Pulmonar/tratamento farmacológico , Hipertensão Arterial Pulmonar/induzido quimicamente , Hipertensão Arterial Pulmonar/metabolismo , Células Cultivadas , Estresse Oxidativo/efeitos dos fármacos , Apoptose/efeitos dos fármacos , Purina-Núcleosídeo Fosforilase/metabolismo , Hipertensão Pulmonar/tratamento farmacológico , Hipertensão Pulmonar/induzido quimicamente , Hipertensão Pulmonar/metabolismo , Adenosilmetionina Descarboxilase/metabolismo , Modelos Animais de Doenças , HumanosRESUMO
Purpose: The underlying causes of pulmonary arterial hypertension (PAH) often remain obscure. Addressing PAH with effective treatments presents a formidable challenge. Studies have shown that Hydroxysafflor yellow A (HSYA) has a potential role in PAH, While the mechanism underlies its protective role is still unclear. The study was conducted to investigate the potential mechanisms of the protective effects of HSYA. Methods: Using databases such as PharmMapper and GeneCards, we identified active components of HSYA and associated PAH targets, pinpointed intersecting genes, and constructed a protein-protein interaction (PPI) network. Core targets were singled out using Cytoscape for the development of a model illustrating drug-component-target-disease interactions. Intersection targets underwent analysis for Gene Ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Selected components were then modeled for target interaction using Autodock and Pymol. In vivo validation in a monocrotaline-induced PAH (MCT-PAH) animal model was utilized to substantiate the predictions made by network pharmacology. Results: We associated HSYA with 113 targets, and PAH with 1737 targets, identifying 34 mutual targets for treatment by HSYA. HSYA predominantly affects 9 core targets. Molecular docking unveiled hydrogen bond interactions between HSYA and several PAH-related proteins such as ANXA5, EGFR, SRC, PPARG, PGR, and ESR1. Conclusion: Utilizing network pharmacology and molecular docking approaches, we investigated potential targets and relevant human disease pathways implicating HSYA in PAH therapy, such as the chemical carcinogenesis receptor activation pathway and the cancer pathway. Our findings were corroborated by the efficacious use of HSYA in an MCT-induced rat PAH model, confirming its therapeutic potential.
Assuntos
Chalcona , Chalcona/análogos & derivados , Medicamentos de Ervas Chinesas , Hipertensão Arterial Pulmonar , Quinonas , Humanos , Animais , Ratos , Hipertensão Arterial Pulmonar/induzido quimicamente , Hipertensão Arterial Pulmonar/tratamento farmacológico , Remodelação Vascular , Simulação de Acoplamento Molecular , Chalcona/farmacologiaRESUMO
The serum ferritin (SF) levels of patients with hepatic alveolar echinococcosis (HAE) were compared to the laboratory reference value, and the correlation between SF and associated parameters in patients with HAE was assessed. Hematological and imaging data of 245 patients with HAE were collected. Patients were classified into the LSF group (SF ≤ 204 ng/ml) or HSF group (SF > 204 ng/ml) according to the level of SF. There was no significant difference in the serum iron level between groups (P > 0.05). Significant differences in unsaturated iron-binding capacity (UIBC), liver function, blood coagulation, lipid, blood cell count, and lesion characteristics were observed (P < 0.05). Correlation analysis showed that SF was related to UIBC, γ-glutamyl transferase, total bilirubin (TBIL), direct bilirubin (DBIL), fibrinogen (FIB), neutrophil count, and maximal lesion diameter (all absolute rs ≥ 0.4). The correlation coefficient between SF and UIBC showed the highest absolute value (rs = -0.556, P < 0.001). Single-factor linear regression analysis showed that TBIL and DBIL showed the R2 values were 0.221 and 0.220, and the R2 values of UIBC, FIB, and maximal lesion diameter were 0.157, 0.174, and 0.167, respectively, and those of the remaining indicators were <0.1. Multi-factor binary logistic regression analysis showed that UIBC (P < 0.001, OR = 0.909), FIB (P = 0.020, OR = 1.662), hemoglobin (HGB) (P = 0.002, OR = 1.029), and maximal lesion diameter (P = 0.002, OR = 1.146) were significant factors influencing SF abnormalities. SF levels in some patients with HAE were higher than the laboratory reference value. Correlation and regression analysis of SF suggested that the UIBC, FIB, HGB, and maximal lesion diameter were related to SF and affected the SF level. These results may be helpful for the diagnosis and severity assessment of HAE in the future.
Assuntos
Equinococose Hepática , Equinococose Hepática/diagnóstico por imagem , Ferritinas , HumanosRESUMO
A supramolecular polymer, poly(N-acryloyl glycinamide) (PNAGA), with a bisamide group on each side of the chain forming multiple amide-hydrogen bonds was synthesized in this work as a binder for silicon (Si)-based anodes. This supramolecular polymer binder with improved mechanical properties presents good interfacial adhesion with Si particles forming hydrogen bonds and enhances the adhesive strength between the electrode material film and the copper current collector. Benefiting from the highly stable inter- and intramolecular multiple amide-hydrogen bonds of the PNAGA binder, the electrode structure maintains integrity and a stable solid electrolyte interphase (SEI) layer is formed on the surface of Si particles. The effect of different binders on the composition of the SEI film was also investigated by X-photoelectron spectroscopy (XPS) characterization. In comparison with polyacrylamide (PAM), which has a similar structure to PNAGA, and the traditional sodium alginate (SA) binder, the Si electrode containing the PNAGA binder shows improved electrochemical performance. The capacity retention is 84% after 100 cycles at 420 mA g-1, and the capacity remains at 1942.6 mAh g-1 after 400 cycles at 1260 mA g-1. Even with a mass loading of 1.2 mg cm-2 Si, the electrode with the PNAGA binder exhibits high initial areal capacity (2.64 mAh cm-2) and good cycling performance (81% capacity retention after 50 cycles). Moreover, the application of the PNAGA binder also brings a stable cycle performance to the commercial Si-graphite (SiC) anode material.
RESUMO
Binders play a crucial role in the development of silicon (Si) anodes for lithium-ion batteries with high specific energy. The large volume change of Si (â¼300%) during repeated discharge and charge processes causes the destruction and separation of electrode materials from the copper (Cu) current collector and ultimately results in poor cycling performance. In the present study, we design and prepare hydrogen-bonding cross-linked thiourea-based polymeric binders (denoted CMC-co-SN) in consideration of their excellent binding interaction with the Cu current collector and low cost as well. The CMC-co-SN binders are formed through in situ thermopolymerization of chain-type carboxymethylcellulose sodium (CMC) with thiourea (SN) in the drying process of Si electrode disks. A tight and physical interlocked layer between the CMC-co-SN binder and Cu current collector is derived from a dendritic nonstoichiometric copper sulfide (CuxS) layer on the interface and enhances the binding of electrode materials with the Cu current collector. When applying the CMC-co-SN binders to micro- (â¼3 µm) (µSi) and nano- (â¼50 nm) (nSi) Si particles, the Si anodes exhibit high initial Coulomb efficiency (91.5% for µSi and 83.2% for nSi) and excellent cyclability (1121 mA h g-1 for µSi after 140 cycles and 1083 mA h g-1 for nSi after 300 cycles). The results demonstrate that the CMC-co-SN binders together with a physical interlocked layer have significantly improved the electrochemical performance of Si anodes through strong binding forces with the current collector to maintain electrode integrity and avoid electric contact loss.
RESUMO
Currently, lithium-ion batteries (LIBs) are assembled with polar electrolytes; thus, resulting SEI layers are dominated with organics. Herein, a low-polarity electrolyte is formulated with a low-polarity solvent (tetraethyl silicate, TEOS) and a non-polar inert shielding co-solvent (cyclohexane, CYH); solvation behaviors of lithium salt are investigated. The use of such a low-polarity solvent is found to improve the fraction of anions in the solvation sheath of Li+, and the presence of the non-polar co-solvent further shields the reductive decomposition of the solvent on the anode. The resulting SEI layer is relatively rich in LiF and has a 3D cross-linked Si-O network as a skeleton from the decomposition of TEOS molecules, which is more robust to tolerate the damage from the volume expansion of silicon. A Si-nanoparticle-based anode in such a low-polarity electrolyte delivers a capacity as high as 1491 mAh g-1 after 200 cycles, outperforming those in the commercial polar electrolytes.